HER2-Positive Gastric Cancer Emerging Therapy and TPP Insights

Thelansis’s “HER2-Positive Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

HER2-Positive Gastric Cancer Overview

HER2-positive gastric cancer refers to a specific subtype of stomach cancer that is characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a gene that plays a role in normal cell growth, but when overexpressed in cancer cells, it can promote the growth and spread of cancer. In gastric cancer, HER2 overexpression is found in a subset of tumors, estimated to be around 10-20% of cases. The overexpression of HER2 is typically assessed through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) testing on a tissue biopsy taken during diagnostic procedures. The significance of HER2 overexpression in gastric cancer is that it can be a predictive biomarker for targeted therapy. Trastuzumab (Herceptin) is a monoclonal antibody targeting the HER2 protein. It is effective in the treatment of HER2-positive gastric cancer, both in advanced and early-stage disease. Patients with HER2-positive gastric cancer may receive a combination of chemotherapy and trastuzumab. The addition of trastuzumab to chemotherapy has been associated with improved survival outcomes in HER2-positive gastric cancer patients.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)